Novo Nordisk set to launch Ozempic in India this month, racing generics

Novo Nordisk, the Danish pharmaceutical giant, is moving fast. The company plans to bring Ozempic to Indian pharmacies this month—a calculated race against the clock and against competitors who are already reshaping the country's weight-loss drug market.

The stakes are enormous. India is home to the world's second-largest population of people with type 2 diabetes, trailing only China. Obesity rates are climbing. Analysts project the global weight-loss treatment market will reach $150 billion annually by the end of this decade, and India represents a critical piece of that growth. For Novo, the December launch of Ozempic is about establishing dominance before cheaper generic versions flood the market and before rivals cement their positions.

Ozempic itself is a once-weekly injectable that the FDA approved in 2017 for type 2 diabetes management. What transformed it into a blockbuster, however, was its off-label use for weight loss. The drug suppresses appetite by mimicking a hormone that slows digestion and prolongs the sensation of fullness. Novo also markets Wegovy, a semaglutide formulation explicitly approved for weight loss. But Ozempic—the diabetes drug—has become the more famous name, partly because of its widespread adoption beyond its original indication.

Novo secured Indian regulatory approval to import and sell Ozempic in September. The company received that clearance knowing the competitive landscape was already shifting. Eli Lilly's Mounjaro, another GLP-1 agonist approved for both diabetes and weight loss, entered the Indian market and quickly dominated. In October alone, Mounjaro sold 262,000 doses compared to just 26,000 doses of Novo's Wegovy, which had launched only four months earlier. The gap was staggering. In response, Novo cut Wegovy's price by up to 37 percent, a defensive move ahead of a more existential threat: the March 2026 expiration of its semaglutide patent.

Once that patent expires, Indian generic manufacturers—Sun Pharma, Cipla, Dr Reddy's, and Lupin among them—will be able to produce their own versions of semaglutide at a fraction of the branded price. That window is closing. Vikrant Shrotriya, Novo Nordisk India's managing director, acknowledged the reality in a statement to Reuters: the company understands India is price-sensitive and is working to position Ozempic competitively. He also noted that Ozempic's arrival would complete Novo's semaglutide portfolio in the country, offering treatment options for both diabetes and obesity.

Novo does have advantages. The company already maintains a strong presence in India's diabetes market through Rybelsus, its semaglutide tablet formulation, and other products. That brand reputation in diabetes therapy gives Novo credibility with prescribers. Analysts suggest Ozempic could be prescribed not only for diabetes and weight loss but also for off-label uses including infertility and sleep apnea—conditions where GLP-1 agonists show promise. Still, the competitive pressure is real. Mounjaro's early dominance suggests that market share in India's weight-loss drug space will be contested fiercely and decided quickly.

The December launch represents Novo's attempt to establish a foothold before generics arrive and before the market fully consolidates around competitors. What happens in the next three months—the pricing Novo sets, the prescriber adoption it achieves, the market share it captures—will shape the company's position in one of the world's most important pharmaceutical markets as it enters a new era of generic competition.